Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629494 · ClinicalTrials.gov registry record · Phase 4
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
A Phase 4 study of Prostate Cancer and PSA, sponsored by Albany Medical College.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 198
- Enrollment target
- 3
- Study locations
NCT05629494 is a Phase 4 study of Prostate Cancer and PSA that is actively recruiting participants, run by Albany Medical College. The registered enrollment target is 198 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05629494, a Phase 4 study of Prostate Cancer and PSA, is actively recruiting participants, sponsored by Albany Medical College.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 198 participants
- Enrollment target
- 3
- Study locations
Study Summary
Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.
Conditions Studied
Interventions
- DRUG Ibuprofen 400 mg, TID
- DIAGNOSTIC_TEST PSA test
Study Locations (3)
Illinois
- University of Chicago Medical Center - Chicago
New York
- Albany Medical Center - Albany
Pennsylvania
- Penn State-Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05629494
The ClinicalTrials.gov registry entry for NCT05629494 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Albany Medical College, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen 400 mg, TID is the first listed.
NCT05629494 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05629494 about?
NCT05629494 is a clinical study titled "Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test". Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at th...
What is the current status of trial NCT05629494?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 198 participants. The study started on 2022-09-27. Estimated completion is 2026-12-01.
What conditions does trial NCT05629494 study?
This clinical trial studies the following conditions: Prostate Cancer, PSA, Prostate Inflammation.
What interventions are being tested in trial NCT05629494?
The interventions under investigation include: Ibuprofen 400 mg, TID (DRUG), PSA test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05629494?
This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05629494 being conducted?
This trial has 3 study locations across Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RECRUITING · Phase 4
-
Gadopiclenol in Contrast Enhanced MRI of the Prostate
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
ACTIVE NOT RECRUITING · Phase 4
-
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.